Andrea Knapp

1.1k total citations
45 papers, 731 citations indexed

About

Andrea Knapp is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Andrea Knapp has authored 45 papers receiving a total of 731 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pathology and Forensic Medicine, 21 papers in Genetics and 20 papers in Oncology. Recurrent topics in Andrea Knapp's work include Lymphoma Diagnosis and Treatment (39 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Viral-associated cancers and disorders (13 papers). Andrea Knapp is often cited by papers focused on Lymphoma Diagnosis and Treatment (39 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Viral-associated cancers and disorders (13 papers). Andrea Knapp collaborates with scholars based in Switzerland, United Kingdom and United States. Andrea Knapp's co-authors include Marek Trněný, Laurie H. Sehn, Tina Nielsen, Umberto Vitolo, Christopher R. Bolen, Deniz Şahin, Maurizio Martelli, Gila Sellam, Federico Mattiello and Robert Marcus and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Andrea Knapp

45 papers receiving 721 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrea Knapp Switzerland	15	553	437	179	136	135	45	731
Christine McIntyre Switzerland	14	202 0.4×	303 0.7×	201 1.1×	146 1.1×	253 1.9×	31	634
Florence Hourcade‐Potelleret Switzerland	16	128 0.2×	195 0.4×	223 1.2×	74 0.5×	140 1.0×	27	567
Yoshikazu Kamiya Japan	10	285 0.5×	385 0.9×	80 0.4×	59 0.4×	19 0.1×	18	583
Daniel Jones United States	9	220 0.4×	114 0.3×	178 1.0×	63 0.5×	12 0.1×	22	468
Jaume Capdevila Spain	18	66 0.1×	277 0.6×	31 0.2×	49 0.4×	101 0.7×	41	1.0k
Bo Lan China	14	78 0.1×	619 1.4×	67 0.4×	68 0.5×	97 0.7×	54	919
Anna Maria Elisabeth Walenkamp Netherlands	9	79 0.1×	271 0.6×	38 0.2×	45 0.3×	26 0.2×	17	467
John Frye United States	10	101 0.2×	286 0.7×	46 0.3×	52 0.4×	30 0.2×	24	754
Xuejun Chen China	14	100 0.2×	161 0.4×	124 0.7×	115 0.8×	10 0.1×	38	545

Countries citing papers authored by Andrea Knapp

Since Specialization

Citations

This map shows the geographic impact of Andrea Knapp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Knapp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Knapp more than expected).

Fields of papers citing papers by Andrea Knapp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Knapp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Knapp. The network helps show where Andrea Knapp may publish in the future.

Co-authorship network of co-authors of Andrea Knapp

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Knapp. A scholar is included among the top collaborators of Andrea Knapp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Knapp. Andrea Knapp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Xiaoyong, Tarec Christoffer El‐Galaly, Lale Kostakoglu, et al.. (2024). Automated Lugano Metabolic Response Assessment in ¹⁸ F-Fluorodeoxyglucose–Avid Non-Hodgkin Lymphoma With Deep Learning on ¹⁸ F-Fluorodeoxyglucose–Positron Emission Tomography. Journal of Clinical Oncology. 42(25). 2966–2977. 6 indexed citations

Kostakoğlu, Lale, Maurizio Martelli, Laurie H. Sehn, et al.. (2023). A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials. SHILAP Revista de lepidopterología. 4(4). 1042–1051. 1 indexed citations

Gormsen, Lars Christian, Lasse Hjort Jakobsen, Toby A. Eyre, et al.. (2023). The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study. British Journal of Haematology. 204(4). 1271–1278. 2 indexed citations

Townsend, William, Wolfgang Hiddemann, Christian Buske, et al.. (2023). Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. HemaSphere. 7(7). e919–e919. 27 indexed citations

Kim, Eugene, Yanwen Jiang, Alexandra Bazeos, et al.. (2022). Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma. BMC Cancer. 22(1). 231–231. 5 indexed citations

Casulo, Carla, Michael Herold, Wolfgang Hiddemann, et al.. (2022). Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study. Clinical Lymphoma Myeloma & Leukemia. 23(1). 40–48. 14 indexed citations

Morschhauser, Franck, Nilanjan Ghosh, Izidore S. Lossos, et al.. (2021). Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial. Blood Cancer Journal. 11(8). 147–147. 16 indexed citations

Kostakoglu, Lale, Federico Mattiello, Maurizio Martelli, et al.. (2021). Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. Haematologica. 107(7). 1633–1642. 37 indexed citations

Barrington, Sally F., Farheen Mir, Tarec Christoffer El‐Galaly, et al.. (2021). Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study. Journal of Nuclear Medicine. 63(8). 1149–1154. 3 indexed citations

10.

Davies, Andrew, Peter C. Trask, Judit Demeter, et al.. (2020). Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma. Annals of Hematology. 99(12). 2837–2846. 9 indexed citations

11.

Klánová, Magdalena, Mikkel Z. Oestergaard, Marek Trněný, et al.. (2019). Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. Clinical Cancer Research. 25(15). 4634–4643. 54 indexed citations

12.

Sehn, Laurie H., Marek Trněný, Kamal Bouabdallah, et al.. (2019). Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study. Blood. 134(Supplement_1). 2822–2822. 3 indexed citations

13.

Pott, Christiane, Eva Hoster, Michael Unterhalt, et al.. (2018). Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients. Blood. 132(Supplement 1). 396–396. 20 indexed citations

14.

Freeman, Ciara L., Sebastian Böttcher, Javier de la Serna, et al.. (2018). Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial. Blood. 132(Supplement 1). 4419–4419. 1 indexed citations

15.

Townsend, William, Christian Buske, Guillaume Cartron, et al.. (2018). Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study. Blood. 132(Supplement 1). 1597–1597. 11 indexed citations

16.

Kostakoglu, Lale, Maurizio Martelli, Laurie H. Sehn, et al.. (2017). Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study. Blood. 130(Suppl_1). 824–824. 20 indexed citations

17.

Dyer, Martin J.S., Marcos González, Martin Dreyling, et al.. (2016). Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. Haematologica. 102(4). 765–772. 21 indexed citations

18.

Knapp, Andrea, et al.. (2008). Effect of Carnitine Deprivation on Carnitine Homeostasis and Energy Metabolism in Mice with Systemic Carnitine Deficiency. Annals of Nutrition and Metabolism. 52(2). 136–144. 13 indexed citations

19.

Török, Michael, et al.. (2007). Hepatic effects of Cimicifuga racemosa extract in vivo and in vitro. Cellular and Molecular Life Sciences. 64(21). 2848–2857. 32 indexed citations

20.

Knapp, Andrea, Konstantin Beier, Luigi Terracciano, et al.. (2007). Toxicity of Valproic Acid in Mice with Decreased Plasma and Tissue Carnitine Stores. Journal of Pharmacology and Experimental Therapeutics. 324(2). 568–575. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact